Gestiva Preterm Birth Drug Could Be Approved In October

FDA granted a six-month priority review to Adeza’s NDA for the progesterone product under the 505(b)(2) pathway.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet